Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-03-31

Clinical Trial Update: A Usability Study of External Neuromodulation With iTEAR100 Generation 2 [Phase 4]

View source ↗

Summary

A Phase 4 usability study of the iTEAR100 Generation 2 external neuromodulation device for dry eye syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • iTEAR100 Generation 2

Snippet

Sponsor: Olympic Ophthalmics, Inc. | Conditions: Dry Eye Syndromes | Phase 4 | Status: UNKNOWN